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Retroviruses create permanently integrated proviruses that exist in the host genome.
Retroviral genomes encode for functionally conserved gag, pro, pol, and env regions,
as well as integrase (IN), which is required for retroviral integration. IN mediates viral
genome insertion through 3′ end processing of the viral DNA and the strand transfer
reaction. This process requires the formation of a pre-integration complex, comprised
of IN, viral DNA, and cellular proteins. Viral insertion causes DNA damage, leading to the
requirement of host DNA repair mechanisms. Therefore, a failure of DNA repair pathways
may result in genomic instability and potentially cause host cell death. Considering
the numerous human diseases associated with genomic instability, the endogenous
retrovirus-K (ERVK) IN should be considered as a putative contributor to DNA damage
in human cells. Future research and drug discovery should focus on ERVK IN activity
and its role in human conditions, such as neurological disease and cancers.
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INTRODUCTION
Retroviruses have mastered the art of horizontal gene transfer. A key viral enzyme in this process
is the retroviral integrase (IN) enzyme which catalyzes the merger of viral and host genomes.
Starting from an RNA genome, retroviruses convert their genetic material into double stranded
DNA (dsDNA) using a virally encoded reverse transcriptase (RT) enzyme. The viral dsDNA is then
transported into the nucleus as part of the pre-integration complex (PIC), which is composed of
both viral and host proteins, including IN (reviewed in Jayappa et al., 2012; Gerard et al., 2013). IN
coordinates processing of the linear viral DNA ends and joining those ends into target host DNA
through a strand transfer reaction (reviewed in Lesbats et al., 2016). Subsequently, DNA lesions are
left in the host genome, which require cellular repair mechanisms to restore genomic integrity.
Aberrant IN activity or imperfect repair mechanisms can leave a host vulnerable to genomic
instability through the accumulation of DNA lesions. This paper provides a perspective on how
the endogenous retrovirus-K (ERVK) IN enzyme may play a role in generating genomic instability
in the context of human disease.
Structure of Retroviral Integrases
The structure of a retroviral IN commonly contains three domains which are the N-terminal
domain (NTD), the central catalytic domain (CCD), and the C-terminal domain (CTD); some
also encode an additional N-terminal extension domain (NED) (reviewed in Lesbats et al., 2016).
The NTD is involved in IN multimerization and contains two conserved histidine (H) and cysteine
(C) residues that form a highly conserved zinc-binding HHCC motif found in all retroviral IN
(Figure 1) (reviewed in Zheng et al., 1996; Lesbats et al., 2016). The CCD contains two highly
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FIGURE 1 | The ERVK integrase (IN) contains conserved motifs required for enzymatic activity. The alignment of ERVK HML-2 IN sequences with intact
open reading frames. Apart from an intact ERVK-10 (chr5 156660395, 5q33.3) (Kitamura et al., 1996), several other genomic loci containing IN were identified and
labeled based on chromosome, position and cytological band: ERVK7 on chr1 155629394, 1q22; ERVK11 on chr3 185565276, 3q27.2; ERVK6b on chr7 4593950,
7p22.1; ERVK6a on chr7 4585446, 7p22.1; ERVK8 on chr8 7500895, 8p23.1; ERVK25 on chr11 101700708, 11q22.1; ERVK21 on chr12 58330476, 12q14.1;
ERVK24 on chr22 18944324, 22q11.21. All chromosomal locations are reflective of the human genome (GRCh38) assembly. The HHCC and DDE motifs present in
the IN enzyme have been annotated in orange and purple, respectively. Blue annotations reflect additional amino acids conserved within retroviral IN proteins.
conserved aspartic acid (D) residues and a glutamic acid (E)
residue that form a catalytic triad called the DDE motif (Hare
et al., 2010). This catalytic triad recognizes and binds to Mg2+
which is essential for proper IN function and multimerization
(reviewed in Lesbats et al., 2016). The acidic residues of the DDE
motif catalyze 3′ linear DNA processing, DNA strand transfer
reactions, and disintegration reactions (reverse of the strand
transfer ligation reaction) – all enzymatic processes required for
a functional IN (Hossain et al., 2013; Wolkowicz et al., 2014). The
CTD is the least conserved domain, although it contains some
conserved tryptophan residues, and is integral to the formation of
the intasome (reviewed in Lesbats et al., 2016). Post-translational
modification of IN enzymes can also impact their activity. For
HIV, acetylation of lysine residues within the CTD by cellular
proteins, p300 and GCN5, enhances the DNA binding capacity
and strand-transfer activity of IN (Cereseto et al., 2005; Suzuki
and Chew, 2012). Additionally, integrase enzymes function in
higher-order multimeric complexes, as determined by protein
analysis and crystallography (Diamond and Bushman, 2005; Li
et al., 2011).
Integrase carries out important enzymatic functions that
integrate reverse-transcribed viral DNA into host cell DNA.
However, IN does not function alone, as the functional PIC
also contains host proteins. In HIV and Moloney murine
leukemia virus (MoMLV), IN is associated with barrier-to-
autointegration factor (BAF), which helps prevent integration
of the viral DNA into itself (Van Maele et al., 2006; Wiebe
and Jamin, 2016). It would be of great interest to determine
whether BAF is a universally utilized mechanism by which
retroviruses are protected from autointegration, or whether
divergent mechanisms have evolved. Retroviruses also utilize host
cell proteins in the identification of suitable integration sites
(reviewed in Kvaratskhelia et al., 2014). Lens epithelium-derived
growth factor (LEDGF) directs HIV IN to target integration
sequences and protects IN from proteolysis (Gerard et al., 2013).
More recently, the bromo- and extra-terminal domain (BET)
proteins have been demonstrated to function in proviral targeting
in MoMLV (De Rijck et al., 2013). The varied preferences
exhibited for retroviral insertion suggests that ERV targeting will
also utilize unique cellular proteins.
Integrase Function and the
Consequences of Failed DNA Lesion
Repair
Integration is carried out in three steps: (i) processing, (ii) joining,
and (iii) host-mediated DNA repair (reviewed in Lesbats et al.,
2016). In the first step of retroviral DNA integration, IN binds
to the linear viral dsDNA to form a stable complex called an
intasome. IN then cleaves two (or three) nucleotides from the
3′ ends of viral dsDNA to produce 3′ hydroxyl groups. Next,
IN coordinates the cleavage of host DNA phosphodiester bonds
and their ligation to the free viral hydroxyl groups. Retroviral
integration is not a perfect process. The strand transfer complex
(STC) leaves behind single-stranded DNA (ssDNA) gaps at the
host-provirus junctures and two 5′ base pair overhang extensions
of the viral DNA. Cellular DNA repair mechanisms are then
required to restore genome integrity (Yoder and Bushman,
2000; reviewed in Lesbats et al., 2016). However, the process by
which the STC is disassembled to allow for DNA repair remains
unknown.
Accumulation of DNA lesions and genomic instability lead
to loss of cellular functionality, and ultimately the death or
transformation of human cells (Hanahan and Weinberg, 2011).
Unrepaired IN-mediated ssDNA lesions are hotspots for the
formation of double stranded breaks (DSB) in the DNA of
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replicating host cells (Ryan et al., 2016). Products of IN activity
such as (i) newly integrated proviruses, (ii) viral episomes
resulting from autointegration (2LTR loops), and (iii) unresolved
lesions in the host genome may signal the host cell to initiate
an innate immune response and definitely signal engagement
of diverse DNA damage repair pathways critical to successful
integration; failure to repair the ssDNA lesions left by IN can
induce apoptosis (Stetson et al., 2008; Bregnard et al., 2014; Ryan
et al., 2016).
Interestingly, DSBs can enhance the integration of HIV DNA
into the host genome when in the presence of catalytically
inactive IN (Ebina et al., 2012; Koyama et al., 2013).
Complementary findings that IN is dispensable for provirus
insertion in the context of DSBs stem from the observation of
enhanced integration of wild-type IN virus when DNA-damaged
cells were treated with the IN inhibitor raltegravir (Koyama et al.,
2013). This study suggests that IN inhibitors are best suited to
prevent DNA damage in healthy cells, and that both inhibition of
RT (formation of viral DNA) and IN would be required in cells
containing DNA lesions.
Mobile Elements in the Human Genome
as a Source of Genomic Instability
The human genome contains many endogenous retroviruses
which potentially encode IN (Seifarth et al., 2005). Additionally,
enzymes encoded by non-LTR retrotransposons are known to
mediate DNA damage in humans (e.g., ORF2p) (Gasior et al.,
2006). Select elements, such as ERVK and long interspersed
nuclear element-1 (LINE-1) are of special interest because of
their retrotranspositional activity in modern humans (Mills
et al., 2007). For example, both ERVs and LINE-1 are active
in the developing human brain, and then repressed in mature
tissues (reviewed in Erwin et al., 2014; Mortelmans et al.,
2016). Both ERVK and LINE-1 are negatively regulated by
members of the APOBEC3 family (Lee et al., 2008; Jones
et al., 2013), and differential activity of these elements has been
independently linked to human disease (Frank et al., 2005;
Douville et al., 2011; Balestrieri et al., 2014; Bundo et al.,
2014). Therefore, it is possible that these mobile elements
generate similar patterns of genomic instability when active.
Although this paper calls attention to the underappreciated
role of ERVK IN, it is not the only endogenous enzyme
which may induce DNA damage and subsequent genomic
instability.
ERVK Encodes a Functional Integrase
The original description of a functional IN in ERVK-10 (HERV-
K10) was by Kitamura et al. (1996). This retroviral enzyme shows
not only terminal cleavage and strand transfer activities of ERVK
LTR substrates, but also of LTRs from the divergent retroviruses,
HIV and RSV (Kitamura et al., 1996). Despite these findings,
there has been an underwhelming interest in ERVK IN and their
potential role in human biology.
Recently, our team sought to determine if additional ERVK
loci related to ERVK-10 (those in the HML-2 clade) encode
potentially active IN enzymes. IN sequences were identified
in the human genome GRCh38 by a tBLASTn search based
on the region of the reconstituted infectious ERVK virus
Pheonix (Dewannieux et al., 2006) which matches the Pfam
entries for each IN domain: NTD (Integrase_Zn, PF02022),
CCD (rve, PF00665), CTD (IN_DBD_C, PF00552). BLAST hits
from the same ERV were merged and extended according to
their alignment by MACSE. Out of the 20 ERVK proviruses
containing a full-length IN ORF, only nine maintained intact
HHCC and DDE active site motifs (Figure 1). All putative ERVK
IN-encoding ORFs contained signature HALTH (HXXXH) and
CTQC (CXXC) sequences for the HHCC motif. Additionally,
all but one of these sequences included a WQMD signature
associated with the first aspartate, and a TDNG signature was
consistently associated with the second aspartate within the
D(X17)D(X35)E motif.
Select mutations within the HIV IN have been shown to
modulate its catalytic activity (class I mutants) (Engelman, 1999).
When comparing amino acid substitutions within mutant HIV
IN enzymes and the consensus ERVK IN sequence, we found
that ERVK IN contains no known inactivating substitutions
that alter the active sites or the activity of 3′ processing, DNA
binding or joining (Konsavage et al., 2007; Li et al., 2012;
Johnson et al., 2013). However, without a clear understanding
of ERVK IN and cellular protein interaction, it is difficult
to interpret which substitutions would impact PIC formation
and STC disassembly. Further, ERVK IN likely plays a role in
processes other than integration, such as enhancement of reverse
transcription and virion assembly (reviewed in Lesbats et al.,
2016).
A model of a single ERVK IN subunit superimposed on the
Mouse Mammary Tumor Virus (MMTV) intasome (Figure 2)
shows that the predicted protein folding results in the expected
domain architecture for betaretroviral IN (Ballandras-Colas et al.,
2016). Moreover, the orientation of key residues forms a clear
active site conformation. The DNA binding affinity of the
ERVK IN may differ from MMTV IN because of a linker
between the NTD and CCD domains that impinges into the
DNA binding site, and may partially explain the more relaxed
substrate specificity of the ERVK IN toward retroviral LTRs
(Kitamura et al., 1996). Without a validated ERVK intasome
model, it will be difficult to predict mutations that may impact
multimerization and drug resistance (reviewed in Lesbats et al.,
2016).
ERVK-Associated Diseases Are
Associated with Genomic Instability
The expression of ERVK IN in human cells is poorly documented.
However, cortical brain tissue from patients with amyotrophic
lateral sclerosis (ALS) contain an enhanced frequency of ERVK
transcripts from proviral loci containing open reading frames
(ORFs) for IN, when compared to controls with systemic disease
(Douville et al., 2011). Moreover, the presence of functional
RT expression in several disease states, including ALS (Douville
et al., 2011) and breast cancer (Golan et al., 2008), alludes to
the possibility of IN co-expression derived from the cleavage of
the ERVK gag-pol polyprotein. The prime limiting factor for the
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FIGURE 2 | Homology model of the ERVK-10 integrase. The ERVK-10 IN (Uniprot P10266) was modeled by homology to the betaretrovirus Mouse Mammary
Tumor Virus (MMTV) intasome (PDB 3JCA). 100 models were produced using Modeller 9.15 using default settings except the maximum distance for
inter-alpha-carbon homology derived constraints was 32 Angstroms and the slow default was used for molecular dynamics. The model with the lowest DOPE score
(−26429) was superimposed onto the template chain (3JCA:A) by their alpha carbon co-ordinates in pymol, and the RMSD between all 260 aligned alpha carbons is
0.275 Å. ERVK backbone carbons and nitrogens are colored so regions matching the Pfam entries Integrase_Zn, rve, and IN_DBD_C match the color of their linear
representation on the ERVK-10 sequence. 3JCA is light red except the template chain is bright red, and the DNA is gray. This figure was produced using Pymol and
GIMP.
identification of ERVK IN in human tissue samples is the lack of
commercially available antibodies for the detection of this viral
protein.
Interestingly, genomic instability is a hallmark of several
ERVK-associated human diseases, including ALS (Deng et al.,
2014; Maizels, 2015), schizophrenia (Smith et al., 2010; Kushima
et al., 2016) and cancers (Romanish et al., 2010; Mullins and
Linnebacher, 2012). Although proposed mechanisms for DNA
damage do exist for these conditions, they do not preclude the
involvement of ERVK IN. Conceivably, if the ERVK IN is shown
to mediate DNA damage in human disease, this pathology could
potentially be averted through the use of viral IN inhibitors
(Gunthard et al., 2016; Kanters et al., 2016). Concrete evidence
of efficacy against ERVK-driven genomic instability would be a
landmark step toward developing viable therapeutic options for
the treatment of these diseases.
Moreover, certain genetic backgrounds may be more
susceptible to ERVK IN-driven DNA damage. STC disassembly
is required for DNA damage response proteins to access lesion
sites (reviewed in Lesbats et al., 2016). However, while little
is known about the disassembly process, there is reason to
believe that this process utilizes host cell proteins to target IN
for degradation through ubiquitination or phosphorylation
(Mousnier et al., 2007; Suzuki and Chew, 2012). Many of the
ERVK-associated diseases are characterized by impairment
of ubiquitination or abrogated proteasome function, such as
in schizophrenia (Rubio et al., 2013) and ALS (Chang and
Monteiro, 2015; Ciechanover and Kwon, 2015). Blockade of
these pathways would be consistent with a failure to degrade
IN complexes and disallow DNA repair proteins from restoring
lesioned areas of the genome. Similarly, direct alterations
within DNA repair systems, as seen in numerous forms of
cancer (Lord and Ashworth, 2012; O’Connor, 2015), may
favor the buildup of DNA damage in the context of ERVK IN
expression.
Therapeutic Value of Integrase Inhibitors
in ERVK-Associated Disease
It is tantalizing to imagine how currently used anti-retroviral
drugs could be repurposed for the treatment of clinically
challenging conditions, such as ALS and cancers. In recent
years, the adoption of IN strand transfer inhibitor (InSTI) for
the treatment of HIV has come to the forefront (Gunthard
et al., 2016), in part due to their improved blood–brain
barrier permeability as compared to protease and RT
inhibitors (Varatharajan and Thomas, 2009; Meeker et al.,
2014; Nightingale et al., 2014). For example, the IN inhibitor
dolutegravir has been shown to cross the blood–brain barrier,
resulting in therapeutic concentrations in the cerebrospinal
fluid (CSF) similar to those found in plasma (Letendre et al.,
2014). This highlights the potential use of IN inhibitors
for arresting progression of ERVK-associated neurological
conditions.
Concern surrounding the rapid appearance of drug-resistance
mutations in exogenous retroviruses commonly limits the
therapeutic potential of anti-retroviral compounds (Gunthard
et al., 2016; Kanters et al., 2016). However, ERVK is a prisoner
entrapped by the high fidelity of human genomic replication,
thus limiting the appearance of drug resistance mutations
and improving the therapeutic potential for IN inhibitors in
ERVK-mediated disease. Future identification of candidate IN
inhibitors for clinical drug trials in ERVK-associated disease
will provide a substantive contribution toward the development
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of effective (and desperately needed) treatment options for
refractory conditions, such ALS and cancers.
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